Ependymoma Drug Market to Surpass US$ 208.4 Mn by 2030 With CAGR of 4.8% | Fera Pharmaceuticals, Pfizer, Novartis AG, Merck KGaA.

A particular kind of tumour called an epidermoma can develop in the brain or spinal cord. The ependymal cells that line the spinal cord’s core and the ventricles of the brain give rise to ependymomas. Ependymoma can develop at any age, however it most frequently affects kids under the age of five.

The market for drugs used to treat ependymomas is anticipated to reach US$ 143.0 million in 2022 and grow at a CAGR of 4.8% during the following five years (2022-2030).

During the forecast period, rising ependymoma prevalence is anticipated to fuel market expansion.

Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/5332

Over the forecast period, rising ependymoma prevalence is anticipated to fuel market expansion for ependymoma medications. For instance, ependymoma, which accounts for roughly 5% of all childhood brain tumours, most frequently affects young children, according to statistics published by the American Society of Clinical Oncology in January 2022. In the United States, 250 kids and teenagers under the age of 19 would have an ependymoma diagnosis in 2022.

Increasing product approvals from regulatory bodies for the treatment of ependymoma are anticipated to fuel market expansion over the course of the projected period.

The worldwide ependymoma medication market is anticipated to rise over the course of the forecast period as a result of an increase in the number of products approved for the treatment of ependymoma.

For instance, clinical stage pharmaceutical company Moleculin Biotech, Inc. announced in April 2021 that the FDA has designated its p-STAT3 inhibitor, WP1066, for the treatment of ependymoma, as a rare paediatric disease (RPD).

Impact

The worldwide ependymoma medication market’s supply chain has been adversely impacted by this shortage of raw materials and components. Therefore, it is anticipated that the COVID-19 pandemic will negatively affect the ependymoma medication market’s supply chain. According to a study that was conducted to assess the effects of COVID-19 on pharmaceutical systems and supply chains in resource-constrained countries in Sub-Saharan countries like Namibia, it was reported in an article published in the Exploratory Research in Clinical and Social Pharmacy journal in June 2021. For instance, the COVID-19 pandemic has significantly impacted global medicine shortages and manufacturing prices, according to a review study in the European Pharmaceutical Review Journal from November 2020. Additionally, according to the same source, the COVID-19 pandemic has caused issues with drug stockpiling, delayed transit, and other issues.

Market Restraint

The negative effects of the treatment are one of the main factors preventing the growth of the global ependymoma drug market. Dexamethasone, a corticosteroid used to treat ependymoma, has a number of undesirable side effects, such as nausea, vomiting, headaches, vertigo, sleeplessness, restlessness, depression, anxiety, acne, faster hair growth, and susceptibility to bruising.

Key Players

Moleculin Biotech, Inc., Fera Pharmaceuticals, APOTEX INC, Pfizer, UCB, Inc., Novartis AG, Lupin Pharmaceuticals, Inc., Merck KGaA, Zydus Cadila, Baxter, and Cipla Limited are important market participants.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/5332

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Ependymoma Drug Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Ependymoma Drug Industry Impact

Chapter 2 Global Ependymoma Drug Competition by Types, Applications, and Top Regions and Countries
2.1 Global Ependymoma Drug (Volume and Value) by Type
2.3 Global Ependymoma Drug (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Ependymoma Drug Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Ependymoma Drug Market Analysis
Chapter 6 East Asia Ependymoma Drug Market Analysis
Chapter 7 Europe Ependymoma Drug Market Analysis
Chapter 8 South Asia Ependymoma Drug Market Analysis
Chapter 9 Southeast Asia Ependymoma Drug Market Analysis
Chapter 10 Middle East Ependymoma Drug Market Analysis
Chapter 11 Africa Ependymoma Drug Market Analysis
Chapter 12 Oceania Ependymoma Drug Market Analysis
Chapter 13 South America Ependymoma Drug Market Analysis
Chapter 14 Company Profiles and Key Figures in Ependymoma Drug Business
Chapter 15 Global Ependymoma Drug Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology